1,057 results on '"Gibbons, Don L."'
Search Results
2. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights
3. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
4. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
5. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
6. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer
7. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept
8. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing
9. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
10. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma
11. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages
12. Archival single-cell genomics reveals persistent subclones during DCIS progression
13. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
14. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.
15. PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma
16. Cellular Architecture on Whole Slide Images Allows the Prediction of Survival in Lung Adenocarcinoma
17. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer
18. EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer
19. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
20. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment
21. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
22. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer
23. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
24. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
25. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
26. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes
27. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features
28. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
29. Abstract A022: Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA
30. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology
31. Deep learning-based prediction of the T cell receptor–antigen binding specificity
32. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival
33. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma
34. Cellular Architecture on Whole Slide Images Allows the Prediction of Survival in Lung Adenocarcinoma
35. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC
36. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
37. Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis
38. CD8+ T cells inhibit metastasis and CXCL4 regulates its function
39. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
40. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC
41. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
42. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors.
43. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC
44. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
45. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
46. A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
47. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities
48. Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
49. Supplementary Table S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
50. Data from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.